首页> 外文期刊>Apoptosis: An international journal on programmed cell death >15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation
【24h】

15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation

机译:15-脱氧-Delta(12,14)-前列腺素J(2)(15d-PGJ(2))通过Akt下调使人类白血病HL-60细胞对肿瘤坏死因子相关凋亡诱导配体(TRAIL)诱导的凋亡敏感

获取原文
获取原文并翻译 | 示例
           

摘要

While tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising new agent for the treatment of cancer, resistance to TRAIL remains a therapeutic challenge. Identifying agents to use in combination with TRAIL to enhance apoptosis in leukemia cells would increase the potential utility of this agent as a therapy for leukemia. Here, we show that 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a natural ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma), can sensitize TRAIL-resistant leukemic HL-60 cells to TRAIL-induced apoptosis. The sensitization to TRAIL-induced apoptosis by 15d-PGJ(2) was not blocked by a PPAR gamma inhibitor (GW9662), suggesting a PPAR gamma-independent mechanism. This process was accompanied by activation of caspase-8, caspase-9, and caspase-3 and was concomitant with Bid and PARP cleavage. We observed significant decreases in XIAP, Bcl-2, and c-FLIP after cotreatment with 15d-PGJ(2) and TRAIL. We also observed the inhibition of Akt expression and phosphorylation by cotreatment with 15d-PGJ(2) and TRAIL. Furthermore, inactivation of Akt by Akt inhibitor IV sensitized human leukemic HL-60 cells to TRAIL, indicating a key role for Akt inhibition in these events. Taken together, these findings indicate that 15d-PGJ(2) may augment TRAIL-induced apoptosis in human leukemia cells by down-regulating the expression and phosphorylation of Akt.
机译:尽管肿瘤坏死因子(TNF)相关的凋亡诱导配体(TRAIL)是治疗癌症的有前途的新药,但对TRAIL的耐药性仍然是治疗上的挑战。与TRAIL结合使用以增强白血病细胞凋亡的鉴定试剂将增加该试剂作为白血病疗法的潜在效用。在这里,我们显示15-脱氧-Delta(12,14)-前列腺素J(2)(15d-PGJ(2)),过氧化物酶体增殖物激活受体γ(PPAR gamma)的天然配体可以使TRAIL耐药白血病HL-60细胞能诱导TRAIL凋亡。 PPARγ抑制剂(GW9662)并未阻止15d-PGJ(2)对TRAIL诱导的细胞凋亡的敏化作用,这提示了PPARγ独立的机制。此过程伴随caspase-8,caspase-9和caspase-3的激活,并伴随Bid和PARP裂解。我们观察到与15d-PGJ(2)和TRAIL共同治疗后,XIAP,Bcl-2和c-FLIP明显降低。我们还观察到与15d-PGJ(2)和TRAIL共同处理对Akt表达和磷酸化的抑制作用。此外,Akt抑制剂IV使Akt失活使人类白血病HL-60细胞对TRAIL敏感,这表明在这些事件中Akt抑制的关键作用。综上所述,这些发现表明15d-PGJ(2)可能通过下调Akt的表达和磷酸化来增强TRAIL诱导的人类白血病细胞凋亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号